Trials / Unknown
UnknownNCT05223582
Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 34 (estimated)
- Sponsor
- Fudan University · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety and efficacy of fluzoparib combined with abiraterone in neoadjuvant treatment of patients with high-risk locoregional prostate cancer. Dr. Yao Zhu from Fudan University Shanghai Cancer Center is the co-leading PI of this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Abiraterone acetate | Patients would be treated with 1000mg abiraterone qd. |
| DRUG | Fluzoparib | Patients would be treated with 150mg fluzoparib bid. |
| DRUG | Prednisone | Patients would be treated with 5mg prednisone bid. |
| DRUG | Androgen deprivation therapy | Patients would get medical castration. |
| PROCEDURE | Radical Prostatectomy | Patients would get radical prostatectomy after the neoadjuvant treatment. |
Timeline
- Start date
- 2021-05-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-01
- First posted
- 2022-02-04
- Last updated
- 2023-12-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05223582. Inclusion in this directory is not an endorsement.